(Reuters) - Repligen said the United States District Court for the District of Massachusetts issued a favorable ruling on a sanctions motion filed by Repligen and the Massachusetts Institute of Technology against ImClone based on conduct that Repligen argued constituted intimidation of a central witness in a patent infringement case over ImClone's cancer drug Erbitux.
The court found that ImClone lawyers attempted to block the cooperation of a key witness and that the actions prejudiced Repligen and MIT from fully prosecuting their case.
Read more at Reuters.com Government Filings News
The court found that ImClone lawyers attempted to block the cooperation of a key witness and that the actions prejudiced Repligen and MIT from fully prosecuting their case.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment